Nucleic Acid Synthesis Inhibitors - Microbiology

SECTION 1

Historical Context & Motivation

The discovery of antibiotics that target nucleic acid synthesis represents one of the most consequential chapters in antimicrobial pharmacology. Throughout much of the twentieth century, clinicians relied primarily on agents that disrupted cell wall assembly or protein translation, but the emergence of resistant pathogens demanded novel strategies. Researchers recognized that DNA replication and RNA transcription were essential bacterial processes that offered attractive targets for selective toxicity. Exploiting the structural and enzymatic differences between prokaryotic and eukaryotic nucleic acid machinery became a central goal of antimicrobial drug development. The resulting classes of drugs—quinolones, rifamycins, metronidazole, and others—now constitute frontline therapies for infections ranging from tuberculosis to urinary tract infections.

1962 • Nalidixic Acid Synthesized

George Lesher discovers nalidixic acid, the first quinolone antibiotic, as a by-product of chloroquine synthesis. It is introduced clinically for urinary tract infections, establishing the quinolone drug class.

1963 • Rifamycins Enter Clinical Use

Rifampicin (rifampin), derived from Amycolatopsis mediterranei, is developed as a potent inhibitor of bacterial RNA polymerase. It soon becomes a cornerstone of tuberculosis treatment regimens worldwide.

1980s • Fluoroquinolone Revolution

The addition of a fluorine atom at the C-6 position of the quinolone scaffold yields ciprofloxacin and norfloxacin, dramatically enhancing potency and broadening the antimicrobial spectrum to include gram-negative and some gram-positive organisms.

1999 • Fidaxomicin Discovery

Fidaxomicin, a macrocyclic antibiotic targeting bacterial RNA polymerase with a narrow spectrum of activity, is identified as a promising agent against Clostridioides difficile, illustrating the continued innovation within nucleic acid synthesis inhibitors.

2010s–Present • Resistance and New Strategies

Widespread fluoroquinolone resistance, particularly via plasmid-mediated qnr genes and target mutations, drives research into novel topoisomerase inhibitors and RNA polymerase inhibitors that evade existing resistance mechanisms.

The central question that motivated this entire drug class remains relevant today: how can we selectively disrupt bacterial nucleic acid synthesis—the replication and expression of the genome—while sparing the analogous processes in human cells? The answer lies in understanding the structural distinctions between prokaryotic and eukaryotic enzymes such as DNA gyrase, topoisomerase IV, and DNA-dependent RNA polymerase.

SECTION 2

Core Principles & Definitions

Nucleic acid synthesis inhibitors encompass any antimicrobial agent that interferes with the replication of DNA or the transcription of DNA into RNA within bacterial cells. These drugs achieve selective toxicity because the enzymes they target in prokaryotes are structurally distinct from their eukaryotic counterparts. Understanding this class requires familiarity with several foundational concepts that underpin their mechanism, spectrum, and clinical utility.

Selective Toxicity

The principle that an effective antimicrobial must harm the pathogen while causing minimal damage to host cells. Nucleic acid synthesis inhibitors exploit differences between bacterial type II topoisomerases and bacterial RNA polymerase versus their eukaryotic homologs to achieve this selectivity.

DNA Gyrase & Topoisomerase IV

DNA gyrase (topoisomerase II) introduces negative supercoils to relieve torsional strain during replication, while topoisomerase IV decatenates daughter chromosomes after replication. Both are essential type II topoisomerases in bacteria and primary targets of fluoroquinolones.

DNA-Dependent RNA Polymerase

The bacterial RNA polymerase holoenzyme (core enzyme + σ factor) transcribes DNA into mRNA. Rifamycins bind the β-subunit of this enzyme, blocking the elongation of RNA chains. Eukaryotic RNA polymerases lack the rifamycin-binding pocket, ensuring selectivity.

Bactericidal vs. Bacteriostatic

Fluoroquinolones are typically bactericidal, generating double-strand DNA breaks when the drug traps the topoisomerase–DNA complex. Rifamycins are also bactericidal at therapeutic concentrations. This distinction influences clinical decision-making, particularly in immunocompromised patients.

Resistance Mechanisms

Resistance to nucleic acid synthesis inhibitors arises through target modification (e.g., mutations in gyrA or rpoB), efflux pumps, plasmid-mediated protective proteins (Qnr), and enzymatic modification. Understanding these mechanisms is essential for stewardship and new drug design.

✦

KEY TAKEAWAY

Think of bacterial DNA replication as a highway construction project: DNA gyrase is the crew that manages the twisting and untwisting of road segments, while RNA polymerase is the fleet of trucks reading the blueprint and delivering materials. Fluoroquinolones lock the road crew onto the pavement, causing a fatal traffic pileup (double-strand breaks). Rifamycins disable the delivery trucks by blocking the ignition (the β-subunit), halting all mRNA production. In both cases, the drug exploits features of the bacterial machinery that differ from the human version, so the antibiotic targets the pathogen's 'construction crew' without interfering with the host's.

SECTION 3

Visual Explanation: Targets of Nucleic Acid Synthesis Inhibitors

This diagram illustrates the two primary targets within a bacterial cell. At the DNA replication fork (upper region), fluoroquinolones trap DNA gyrase (pink circle) and topoisomerase IV (amber circle) on the DNA, converting them into lethal agents that fragment the chromosome. In the transcription complex (lower region), rifamycins bind the β-subunit of RNA polymerase (green rectangle), blocking mRNA elongation.

The diagram above encapsulates the dual strategies employed by nucleic acid synthesis inhibitors. Fluoroquinolones stabilize the covalent complex that type II topoisomerases form with cleaved DNA, converting an essential enzyme into a source of cytotoxic double-strand breaks—a mechanism sometimes described as 'poisoning' the enzyme rather than merely inhibiting it. In contrast, rifamycins physically occlude the RNA exit channel of the RNA polymerase β-subunit, preventing the nascent transcript from extending beyond two to three nucleotides. Both mechanisms are lethal because they target enzymes that are indispensable at every round of replication and transcription, and the prokaryotic versions of these enzymes differ sufficiently from their eukaryotic counterparts to allow selective targeting at clinically achievable drug concentrations.

SECTION 4

Mechanisms of Action in Detail

Fluoroquinolones: Topoisomerase Poisoning

Fluoroquinolones exert their bactericidal effects through a sophisticated mechanism that goes beyond simple enzyme inhibition. During normal DNA replication, DNA gyrase (composed of GyrA and GyrB subunits) introduces transient double-strand breaks in DNA, passes a segment of the duplex through the break, and then reseals the break—thereby introducing negative superhelical tension ahead of the replication fork. Fluoroquinolones intercalate at the enzyme–DNA interface and stabilize the cleaved intermediate, forming a ternary drug–enzyme–DNA complex. The breaks become irreversible once the replication fork collides with the trapped complex, fragmenting the chromosome and triggering the SOS response and, ultimately, cell death. In gram-negative bacteria, DNA gyrase is typically the primary target, whereas in gram-positive organisms, topoisomerase IV (ParC/ParE) is often the preferential target.

Rifamycins: RNA Polymerase Blockade

Rifampicin and its derivatives bind deep within the DNA/RNA channel of the bacterial RNA polymerase β-subunit (encoded by rpoB). This binding site is approximately 12 Å from the active site, and the drug physically blocks the path of the elongating RNA chain once it reaches a length of two to three nucleotides. Importantly, rifamycins do not prevent promoter binding or the formation of the first phosphodiester bond; rather, they sterically occlude the exit channel, causing abortive initiation. The bacterial RNA polymerase core enzyme (α₂ββ'ω) shares no structural homology with eukaryotic RNA polymerases I, II, or III in the rifamycin-binding region, which is the basis for selective toxicity.

Metronidazole: DNA Damage via Reactive Intermediates

Metronidazole represents a distinct mechanism within this class. It is a prodrug that requires reductive activation by low-redox-potential electron transport proteins (e.g., ferredoxin or flavodoxin) found exclusively in anaerobic or microaerophilic organisms. Upon reduction, the nitro group of metronidazole accepts electrons, generating cytotoxic nitroso radicals and hydroxylamine intermediates that directly damage DNA by causing strand breakage, helix destabilization, and inhibition of DNA repair enzymes. Because aerobic cells lack the low-redox electron carriers needed for activation, metronidazole is selectively toxic to anaerobes such as Bacteroides fragilis and protozoa such as Giardia lamblia.

Mechanistic flowchart comparing three classes of nucleic acid synthesis inhibitors. Each pathway leads to cell death but through distinct molecular mechanisms: fluoroquinolones poison topoisomerases, rifamycins block RNA polymerase, and metronidazole generates DNA-damaging radicals.

SECTION 5

Detailed Classification of Drug Classes

Nucleic acid synthesis inhibitors can be organized into several major classes based on their molecular targets, chemical structures, and clinical applications. The following table provides a comprehensive classification that highlights the key differences in target, spectrum, and representative agents within each class. Understanding these distinctions is clinically essential because the choice of drug depends on the pathogen's identity, the infection site, and the patient's comorbidities.

Drug Class	Primary Target	Representative Agents	Spectrum / Key Uses
Fluoroquinolones	DNA gyrase (GyrA/GyrB); Topoisomerase IV (ParC/ParE)	Ciprofloxacin, Levofloxacin, Moxifloxacin, Delafloxacin	Broad spectrum (gram-negative and gram-positive); UTIs, respiratory infections, intra-abdominal infections
Rifamycins	DNA-dependent RNA polymerase β-subunit (rpoB)	Rifampicin (Rifampin), Rifabutin, Rifapentine, Rifaximin	Mycobacterium tuberculosis (first-line); Staphylococcal prosthetic device infections (adjunctive); Rifaximin for hepatic encephalopathy and traveler's diarrhea
Nitroimidazoles	DNA (direct damage via reactive intermediates after reductive activation)	Metronidazole, Tinidazole, Secnidazole	Anaerobic bacteria (Bacteroides, Clostridium); Protozoa (Giardia, Trichomonas, Entamoeba)
Fidaxomicin	RNA polymerase σ-subunit interaction region (distinct site from rifamycins)	Fidaxomicin	Narrow spectrum; Clostridioides difficile infection (CDI); minimal effect on gut microbiome
Novobiocin (historical)	DNA gyrase B-subunit (ATPase domain)	Novobiocin (largely withdrawn)	Staphylococci; largely replaced by safer agents but conceptually important

Classification of nucleic acid synthesis inhibitors by mechanism, representative drugs, and clinical spectrum

Generational Classification of Quinolones

The quinolone class has evolved through four recognized generations. First-generation quinolones (e.g., nalidixic acid) had narrow gram-negative spectra and were limited to urinary tract infections due to poor systemic tissue penetration. Second-generation agents (ciprofloxacin, norfloxacin) introduced fluorine at C-6, dramatically improving potency, bioavailability, and expanding the gram-negative spectrum while adding some gram-positive coverage. Third-generation agents (levofloxacin) further improved gram-positive and atypical pathogen coverage. Fourth-generation agents (moxifloxacin) added anaerobic activity while retaining broad-spectrum efficacy, making them useful respiratory fluoroquinolones. Each generation reflects deliberate modifications to the bicyclic quinolone scaffold that alter pharmacokinetics and target binding affinity.

SECTION 6

Worked Example: Clinical Reasoning with Nucleic Acid Synthesis Inhibitors

The following worked example integrates pharmacological knowledge of nucleic acid synthesis inhibitors with clinical decision-making, illustrating how understanding mechanisms and resistance patterns guides antibiotic selection.

Selecting an Appropriate Nucleic Acid Synthesis Inhibitor

1
Step 1 — Identify the Clinical Scenario

A 45-year-old patient presents with a complicated intra-abdominal abscess. Culture results indicate a polymicrobial infection with both Escherichia coli (gram-negative aerobe) and Bacteroides fragilis (gram-negative obligate anaerobe). The E. coli isolate is sensitive to ciprofloxacin (MIC = 0.25 μg/mL), and the B. fragilis isolate is sensitive to metronidazole (MIC = 1 μg/mL). The patient has no drug allergies.

Polymicrobial infection requiring coverage of both aerobes and anaerobes.
2
Step 2 — Match Pathogens to Drug Mechanisms

Ciprofloxacin is a second-generation fluoroquinolone that inhibits DNA gyrase (primary target in gram-negative organisms), making it effective against E. coli. However, ciprofloxacin has limited anaerobic activity because anaerobes have lower topoisomerase sensitivity and the drug's uptake is suboptimal in anaerobic environments. Metronidazole, a nitroimidazole, requires reductive activation by low-redox electron carriers present only in obligate anaerobes and is therefore ideally suited for B. fragilis. Metronidazole has no meaningful activity against aerobic gram-negative rods.

Ciprofloxacin → E. coli via DNA gyrase inhibition; Metronidazole → B. fragilis via reductive DNA damage
3
Step 3 — Evaluate Combination Rationale

The complementary mechanisms make ciprofloxacin plus metronidazole a rational combination for this polymicrobial infection. There is no antagonistic interaction between these two classes because they act on entirely different targets. The combination ensures coverage of both aerobic and anaerobic components of the abscess flora.

Combination therapy is synergistic in coverage without pharmacological antagonism.
4
Step 4 — Anticipate Resistance Considerations

The clinician should monitor for fluoroquinolone resistance in E. coli, which is increasingly common due to chromosomal mutations in gyrA (particularly Ser83 and Asp87) and plasmid-mediated qnr genes. If resistance emerges, alternatives include third-generation cephalosporins or carbapenems. Metronidazole resistance in B. fragilis remains uncommon (< 1% in most surveys) but can arise through nim genes encoding nitroimidazole reductases that convert the drug to an inactive amine.

Monitor for gyrA mutations in E. coli; metronidazole resistance in B. fragilis is rare but encoded by nim genes.
5
Step 5 — Final Therapeutic Decision

Based on susceptibility data, mechanism compatibility, and resistance considerations, the recommended empiric regimen is ciprofloxacin 400 mg IV every 12 hours plus metronidazole 500 mg IV every 8 hours. This regimen provides dual nucleic acid synthesis inhibition through orthogonal mechanisms: topoisomerase poisoning for the aerobe and reductive DNA fragmentation for the anaerobe.

Ciprofloxacin 400 mg IV q12h + Metronidazole 500 mg IV q8h — dual nucleic acid synthesis inhibition with complementary spectra.

SECTION 7

Resistance Mechanisms & Limitations

Resistance to nucleic acid synthesis inhibitors is a growing clinical challenge, driven by both chromosomal mutations and horizontally acquired genetic elements. Understanding the molecular basis of resistance is essential for rational antibiotic stewardship and informs the development of next-generation agents. The following table summarizes the principal resistance mechanisms for each drug class, their genetic basis, and clinical significance.

Resistance Mechanism	Drug Class Affected	Genetic Basis	Clinical Impact
Target modification (QRDR mutations)	Fluoroquinolones	Point mutations in gyrA (Ser83, Asp87) and parC; accumulation of multiple mutations leads to high-level resistance	Most common mechanism; stepwise acquisition; high prevalence in E. coli and Neisseria gonorrhoeae
Plasmid-mediated protection (Qnr)	Fluoroquinolones	qnrA, qnrB, qnrS genes encode pentapeptide repeat proteins that protect topoisomerases from drug binding	Confers low-level resistance; facilitates selection of higher-level chromosomal mutations
Efflux pump upregulation	Fluoroquinolones	Overexpression of AcrAB-TolC (gram-negative) or NorA (gram-positive) efflux systems	Reduces intracellular drug concentration; often contributes to multi-drug resistance phenotypes
rpoB mutations	Rifamycins	Point mutations in the 81-bp rifampicin resistance-determining region (RRDR) of rpoB; most commonly S531L and H526Y	Single-step high-level resistance; mutation rate ~10⁻⁸ per cell division; basis for mandatory combination therapy in TB
nim gene expression	Nitroimidazoles	nim genes encode nitroreductases that convert the nitro group to a non-toxic amine before reactive intermediates form	Still rare (< 1% in Bacteroides); increasing surveillance is warranted

Summary of resistance mechanisms against nucleic acid synthesis inhibitors

⚕

CLINICAL SIGNIFICANCE

Rifampicin resistance emerges rapidly when the drug is used as monotherapy because the mutation rate in rpoB is approximately 10⁻⁸ per cell division—meaning that in a typical tuberculosis cavity containing 10⁸ to 10⁹ bacilli, pre-existing resistant mutants are virtually guaranteed. This is analogous to a manufacturing defect rate: if one in every hundred million units is faulty, a factory producing billions of units will inevitably ship some defective products. This principle is why rifampicin must always be used in combination with at least one other effective anti-tuberculosis agent—the probability that a single organism carries resistance mutations to two drugs simultaneously is on the order of 10⁻⁸ × 10⁻⁸ = 10⁻¹⁶, a vanishingly small number.

SECTION 8

Connection to Advanced Theory & Emerging Agents

The study of nucleic acid synthesis inhibitors connects directly to several advanced areas of microbiology and pharmacology, including structural biology of drug–target interactions, the evolution of resistance networks, and the rational design of next-generation agents. As fluoroquinolone resistance escalates globally, researchers are pursuing novel scaffolds and dual-target strategies that may circumvent existing resistance mechanisms.

Current Understanding	Advanced / Emerging Direction
Fluoroquinolones target gyrase and topo IV separately; spectrum depends on preferential target	Novel bacterial topoisomerase inhibitors (NBTIs) bind a single site shared by gyrase and topo IV, achieving dual-target inhibition that requires two simultaneous mutations for resistance
Rifamycins bind one site on the RNA polymerase β-subunit	Kanglemycins are rifamycin analogs with extended sugar moieties that maintain activity against many rpoB mutants by making additional contacts outside the classic RRDR binding pocket
Metronidazole requires anaerobic activation and has no activity against aerobes	Hybrid nitroimidazole-oxazolidinone agents (e.g., delamanid, pretomanid) combine DNA damage with protein synthesis inhibition for multidrug-resistant tuberculosis
Resistance diagnostics rely on culture-based susceptibility testing (24–72 hours)	Rapid molecular diagnostics (e.g., GeneXpert MTB/RIF) detect rpoB mutations directly from clinical specimens within 2 hours, enabling same-day rifampicin resistance detection

Current knowledge versus emerging developments in nucleic acid synthesis inhibition

The development of novel bacterial topoisomerase inhibitors (NBTIs) represents perhaps the most promising advancement. Unlike fluoroquinolones, NBTIs such as gepotidacin bind at the GyrA–GyrA dimer interface—a site distinct from the fluoroquinolone-binding pocket. This means that existing gyrA mutations conferring fluoroquinolone resistance do not affect NBTI binding. Furthermore, because gepotidacin inhibits both gyrase and topoisomerase IV through the same binding mode, the probability of spontaneous resistance is exceptionally low (approximately 10⁻¹¹ per cell division), making these compounds potentially transformative for the treatment of resistant gram-negative infections.

ℹ

Looking Forward

In advanced microbiology and infectious disease courses, you will encounter detailed structural analyses of drug–target complexes using X-ray crystallography data, pharmacokinetic/pharmacodynamic (PK/PD) modeling of bactericidal activity (AUC/MIC ratios), and the population genetics of resistance evolution. The principles introduced in this lesson—selective toxicity, mechanism-based classification, and resistance prediction—form the conceptual foundation for all of these advanced topics.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why fluoroquinolones are described as 'topoisomerase poisons' rather than simple 'topoisomerase inhibitors.' How does this distinction relate to their bactericidal mechanism?

Show answer

A simple enzyme inhibitor would prevent the topoisomerase from performing its catalytic function, halting DNA replication but leaving the DNA intact. A topoisomerase 'poison,' by contrast, stabilizes the covalent enzyme–DNA cleavage complex, trapping the enzyme on the DNA in a state where the double-strand break is held open. When the replication fork collides with this stalled complex, the transient break becomes a permanent double-strand break, which is a lethal lesion for the bacterial cell. This mechanism converts an essential cellular enzyme into a cytotoxic agent, which explains why fluoroquinolones are rapidly bactericidal rather than merely bacteriostatic. The distinction is critical because it means that higher drug concentrations can paradoxically reduce killing if they inhibit replication fork movement before the fork reaches the trapped complex (the 'paradoxical effect').

Question 2: BASIC CALCULATION

If the spontaneous mutation rate conferring rifampicin resistance (rpoB mutation) is 10⁻⁸ per cell division, and a tuberculosis cavity contains approximately 10⁸ bacilli, how many rifampicin-resistant mutants are expected to be present before treatment begins? Why does this calculation justify combination therapy?

Show answer

The expected number of pre-existing rifampicin-resistant mutants is calculated as: N(resistant) = total population × mutation rate = 10⁸ × 10⁻⁸ = 1. This means that, on average, approximately one rifampicin-resistant mutant already exists in the cavity before any drug exposure. If rifampicin were used alone, this pre-existing mutant would survive and proliferate, leading to treatment failure. Combination therapy with a second agent (e.g., isoniazid, with its own independent resistance mutation rate of ~10⁻⁶) means that for an organism to survive, it would need simultaneous resistance to both drugs: 10⁻⁸ × 10⁻⁶ = 10⁻¹⁴. In a population of 10⁸, the expected number of dual-resistant mutants is 10⁸ × 10⁻¹⁴ = 10⁻⁶, an effectively negligible probability. This multiplicative principle is the mathematical foundation of all multi-drug TB regimens.

Question 3: INTERMEDIATE

A clinician is treating a patient with a gram-positive Staphylococcus aureus prosthetic joint infection. She adds rifampicin to the regimen of vancomycin. However, rifampicin is never used as monotherapy. Explain: (a) what is the primary molecular target of rifampicin in S. aureus, (b) why rifampicin is particularly useful for prosthetic device infections, and (c) what resistance mechanism would be selected if rifampicin were used alone.

Show answer

(a) Rifampicin binds the β-subunit of DNA-dependent RNA polymerase (encoded by rpoB) in S. aureus, blocking the elongation of RNA transcripts by physically occluding the RNA exit channel. (b) Rifampicin is uniquely valuable in prosthetic device infections because it has excellent penetration into biofilms—the structured bacterial communities that adhere to implant surfaces and are recalcitrant to most antibiotics. Rifampicin achieves bactericidal concentrations within biofilms where many other agents cannot reach therapeutic levels. (c) If used as monotherapy, rifampicin resistance would emerge rapidly through single-point mutations in the 81-base-pair rifampicin resistance-determining region (RRDR) of rpoB, most commonly S531L or H526Y. The mutation rate of approximately 10⁻⁸ per cell division means that in any sizable bacterial population, resistant variants pre-exist and would be selected within days of monotherapy initiation.

Question 4: APPLIED

A patient with a liver abscess is found to have Bacteroides fragilis on anaerobic culture. The isolate is susceptible to metronidazole. Explain the complete mechanism by which metronidazole kills B. fragilis, beginning with drug entry into the cell and ending with cell death. Why would this same drug be ineffective against an aerobic organism such as Escherichia coli?

Show answer

Metronidazole enters the B. fragilis cell by passive diffusion across the cell membrane. Inside the cell, the nitro group (−NO₂) of metronidazole serves as an electron acceptor and is reduced by low-redox-potential electron transport proteins, specifically ferredoxin and flavodoxin, which are characteristic of anaerobic metabolism. This reductive activation generates a series of cytotoxic intermediates including the nitroso radical (−NO) and hydroxylamine derivative (−NHOH). These reactive intermediates directly damage DNA by causing strand breakage, helix destabilization, and inhibition of DNA repair enzymes. The accumulation of unrepairable DNA lesions leads to cell death. Metronidazole is ineffective against aerobic organisms like E. coli because aerobic bacteria rely on higher-redox electron carriers (NADH, flavoproteins with higher redox potentials) that cannot reduce the metronidazole nitro group efficiently. Furthermore, any partially reduced intermediates formed in aerobic environments are rapidly re-oxidized by molecular oxygen (futile cycling), regenerating the inactive parent compound before it can damage DNA. Thus, selective toxicity is achieved through the metabolic physiology of the target organism rather than through structural differences in the drug target itself.

Question 5: CRITICAL THINKING

Novel bacterial topoisomerase inhibitors (NBTIs) such as gepotidacin bind at the GyrA–GyrA dimer interface, a site distinct from the fluoroquinolone-binding pocket. Based on your understanding of fluoroquinolone resistance mechanisms, analyze why NBTIs may overcome existing fluoroquinolone resistance and discuss whether you would expect cross-resistance between fluoroquinolones and NBTIs. Additionally, what does the estimated spontaneous resistance frequency of ~10⁻¹¹ for NBTIs imply about the likelihood of combination therapy being necessary?

Show answer

Fluoroquinolone resistance most commonly arises through point mutations in the quinolone resistance-determining region (QRDR) of gyrA (positions Ser83 and Asp87 in E. coli numbering), which alter the fluoroquinolone-binding pocket. Because NBTIs bind at the GyrA–GyrA dimer interface—a structurally distinct site—mutations that confer fluoroquinolone resistance do not alter the NBTI-binding pocket. Therefore, cross-resistance between fluoroquinolones and NBTIs is not expected, and this has been confirmed experimentally: gepotidacin retains activity against fluoroquinolone-resistant isolates with gyrA QRDR mutations. The estimated spontaneous resistance frequency of ~10⁻¹¹ for NBTIs is remarkably low (approximately 1,000-fold lower than for fluoroquinolones at ~10⁻⁸). This extremely low frequency arises because NBTIs inhibit both DNA gyrase and topoisomerase IV through the same binding mechanism, meaning resistance would require simultaneous mutations in both targets. In a typical infection containing 10⁶ to 10⁸ bacteria, the expected number of NBTI-resistant mutants is 10⁶ × 10⁻¹¹ = 10⁻⁵ to 10⁸ × 10⁻¹¹ = 10⁻³—essentially zero pre-existing resistant organisms. This suggests that NBTIs may not require combination therapy to prevent resistance emergence in most clinical scenarios, representing a significant advantage over current agents. However, prudent antimicrobial stewardship principles would still favor combination therapy for high-burden infections such as tuberculosis.

SUMMARY

Lesson Summary

Summary

Nucleic acid synthesis inhibitors are antimicrobial agents that disrupt bacterial DNA replication or RNA transcription. The three major classes operate through distinct mechanisms: fluoroquinolones poison DNA gyrase and topoisomerase IV by stabilizing the cleaved DNA complex and generating lethal double-strand breaks; rifamycins block the β-subunit of RNA polymerase, preventing mRNA elongation beyond two to three nucleotides; and nitroimidazoles (e.g., metronidazole) are reductively activated in anaerobes to generate DNA-damaging radical intermediates. Selective toxicity is achieved because the prokaryotic targets differ structurally from their eukaryotic counterparts.

Resistance arises through target modification (e.g., gyrA QRDR mutations for fluoroquinolones, rpoB RRDR mutations for rifamycins), efflux pump upregulation, plasmid-mediated Qnr proteins, and enzymatic drug inactivation. The high single-step resistance rate for rifamycins (~10⁻⁸) mandates combination therapy in tuberculosis treatment. Emerging agents such as novel bacterial topoisomerase inhibitors (NBTIs) and kanglemycins promise to overcome existing resistance by exploiting alternative binding sites on the same essential targets.